The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

AstraZeneca to acquire Neogene Therapeutics for $320M to develop T cell receptor therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T cell receptor therapies, will be acquired by AstraZeneca.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.
Clinical Roundup

Imfinzi + bevacizumab meets primary endpoint of PFS in phase III liver cancer trial

Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.
Table of Contents

Login

Looking for IP Login?